OKOMERA
Okomera is a biotech start-up that accelerates access to improved, precision-based cancer therapies. It pioneers automation and miniaturization of personalized tumor biopsy studies. This technology was invented and patented by Okomera's co-founders at Ecole Polytechnique. Aimee Wessel, Raphaël Tomas, Charles Baroud, and Sandra Jernström founded the Paris, Ile-de-France-based company in 2020.
OKOMERA
Industry:
Biotechnology Life Science Therapeutics
Founded:
2020-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.okomera.com
Total Employee:
1+
Status:
Active
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Apple Mobile Web Clips Icon Content Delivery Network Euro Typekit OVH Squarespace
Similar Organizations
Apeiron Biologics
Apeiron Biologics is a biotech company that focuses on the discovery and development of novel cancer immunotherapies.
Aukera Therapeutics
Aukera Therapeutics is a biotech company that develops novel therapeutics for patients suffering from mTOR protein related diseases.
T3 Pharmaceuticals
T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments.
Current Advisors List
Current Employees Featured
Founder
Investors List
AGORANOV
AGORANOV investment in Non Equity Assistance - Okomera
Official Site Inspections
http://www.okomera.com
- Host name: 198.202.211.1
- IP address: 198.202.211.1
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Okomera"
Okomera - Crunchbase Company Profile & Funding
Organization. Okomera . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Okomera is a …See details»
Okomera - Find the best cancer treatment for every patient
Okomera is developing an innovative approach to accelerate the development of personalized cancer treatments. The technology allows to test a panel of potential therapies (chemotherapy, …See details»
Okomera - LinkedIn
Okomera | 7,993 followers on LinkedIn. Automated 3D organoid screening technology | We integrate standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug …See details»
Okomera 2025 Company Profile: Valuation, Funding & Investors
Okomera General Information Description. Developer of medical technologies designed to accelerate the development of modern cancer therapies with microfluidic 3D cellular assays. …See details»
Okomera - Contacts, Employees, Board Members, Advisors & Alumni
Okomera is a biotech start-up that accelerates access to improved, precision-based cancer therapies. New. Resources. ... Experience the new Crunchbase, powered by AI . Experience …See details»
Okomera - 2025 Company Profile, Funding & Competitors - Tracxn
Mar 6, 2025 Okomera - Developer of a device for in vitro cancer testing using a microfluidic chip. Raised a total funding of $11.2M over 1 round from 5 investors. Founded by Aimee Wessel, …See details»
Okomera Company Profile: Overview and Full News Analysis
Okomera is a company based in Ile-de-France that specializes in revolutionizing drug discovery and personalized medicine through their innovative technology. They offer an automated 3D …See details»
Okomera - Funding, Financials, Valuation & Investors - Crunchbase
Okomera is a biotech start-up that accelerates access to improved, precision-based cancer therapies. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. ... How much …See details»
Why Okomera will be a game-changer in personalized …
Dec 21, 2023 Okomera is a French biotech specialized in the fight against cancer. With the idea of revolutionizing cancer diagnostic devices, the startup enables the creation of replicas of cancerous tumors on ...See details»
Okomera - VentureRadar
Okomera revolutionizes cancer treatment with its automated 3D organoid screening technology. By integrating standard assays on chip, such as CRISPR and T-cell cytotoxicity, Okomera …See details»
Okomera | Biotech Careers
Automated 3D organoid screening technology that integrates standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and …See details»
Okomera - Products, Competitors, Financials, Employees, …
Okomera develops personalized cancer treatment technologies within the biotechnology sector. Use the CB Insights Platform to explore Okomera's full profile. Okomera - Products, …See details»
Okomera raises €10.2m to develop personalized medicine
Okomera is developing an innovative approach to accelerate the development of personalized cancer treatments. The technology allows to test a panel of potential therapies (chemotherapy, …See details»
Okomera - News & Articles
Jan 27, 2025 Okomera is developing an innovative approach to accelerate the development of personalized cancer treatments. The technology allows to test a panel of potential therapies …See details»
Okomera : les organoïdes pour accélérer la découverte de …
Okomera a annoncé le 16 octobre 2024 l’obtention d’une subvention d’1,5 M€ de Bpifrance, à cheval entre subvention et avance récupérable. Ce financement va permettre de développer …See details»
Okomera lève 10,2 M€ pour prédire les traitements du cancer
Jan 24, 2024 Fondée en 2020 à Paris, Okomera se consacre au développement d'une technologie avancée pour évaluer l'efficacité des traitements contre le cancer. Aujourd’hui …See details»
Okomera - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Okomera is a biotech start-up that accelerates access to improved, precision-based cancer therapies. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log …See details»
Okomera to Present Automated Desktop Organoid Screening …
PARIS, Jan. 28, 2025 /PRNewswire/ -- Okomera is a biotech startup developing cutting-edge solutions for oncology drug discovery and will present their technology in SLAS 2025,in San …See details»
Empowering Personalized Cancer Treatments: Okomera - Medium
Okomera is developing a revolutionary cancer diagnostic machine that enables testing of oncology drugs directly on solid tumor biopsies. Our patented droplet microfluidic technology …See details»
Okomera announces 10 million € fundraise on French TV
Okomera is developing an innovative approach to accelerate the development of personalized cancer treatments. The technology allows to test a panel of potential therapies (chemotherapy, …See details»